BridgeMD
New treatment option for Advanced Thyroid Cancer Patients Who Received Target Therapy
Official title A Retrospective and Prospective Real-world Study of Molecular Typing in the Treatment of Advanced Thyroid Cancer
ClinicalTrials.gov ID: NCT06195228
What this study is testing
What is dabrafenib plus trametinib with or without PD-1 antibody?
dabrafenib plus trametinib with or without PD-1 antibody is an investigational medicine, being studied as a potential treatment for advanced thyroid cancer patients who received target therapy.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This is a retrospective and prospective real-world clinical study of molecular typing in the treatment of advanced thyroid cancer. The retrospective study : Patients with advanced thyroid cancer who received precise treatment in the 24 participated hospitals from January 2020 to December 2023 were retrieved.
- Phase 4: studies an already-approved treatment
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Adults
You may be able to join if
- Patients volunteered to participate in this study and signed informed consent;
- Each center can be enrolled in patients who meet the age of their own practice range, regardless of gender ;
- Histologically diagnosed locally advanced or recurrent / metastatic thyroid cancer that cannot undergo radical surgery meets one of the following...
- Radioiodine-refractory differentiated thyroid cancer (RAIR-DTC);
- Differentiated thyroid carcinoma not suitable for iodine therapy;
You likely can't join if
- Patients who are participating in clinical trials of other drugs;
- There is evidence that the patients are pregnant or lactating;
- Other situations that are not suitable for inclusion in this study.
See the full eligibility criteria
- Patients volunteered to participate in this study and signed informed consent;
- Each center can be enrolled in patients who meet the age of their own practice range, regardless of gender ;
- Histologically diagnosed locally advanced or recurrent / metastatic thyroid cancer that cannot undergo radical surgery meets one of the following requirements:
- Radioiodine-refractory differentiated thyroid cancer (RAIR-DTC);
- Differentiated thyroid carcinoma not suitable for iodine therapy;
- Medullary thyroid carcinoma (MTC);
- poorly differentiated thyroid cancer (PDTC) or anaplastic thyroid cancer (ATC);
- Thyroid-related pathogenic or therapeutic target gene detection was performed before enrollment.
- Patients who are participating in clinical trials of other drugs;
- There is evidence that the patients are pregnant or lactating;
- Other situations that are not suitable for inclusion in this study.
The study team makes the final eligibility decision.
Where it's taking place
- Fuzhou, Fujian, China
- Zhengzhou, Henan, China
- Wuhan, Hubei, China
- Hohhot, Inner Mongolia, China
- Shanghai, Shanghai Municipality, China
- Shanxi, Taiyuan, China
- Hangzhou, Zhejiang, China
- Beijing, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, not specified. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Fuzhou, Fujian, China; Zhengzhou, Henan, China; Wuhan, Hubei, China; Hohhot, Inner Mongolia, China; Shanghai, Shanghai Municipality, China; Shanxi, Taiyuan, China and 2 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.